Abiopharma

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

NeoGenomics Reports Third Quarter 2025 Results

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market

Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025

IQVIA Reports Third-Quarter 2025 Results

Entrada Therapeutics to Present at Upcoming Investor Conferences

Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025

Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch